By browsing our site you agree to our use of cookies. You will only see this message once. Find out more

NHSBT requires pathogen reduced plasma which will then be subsequently manufactured into FFP, Single and pooled cryoprecipitate for paediatric and neonatal use, for recipients born on/after 1.1.1996. Those recipients are deemed not to have been ...

Contract notice

Supplies

Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
NHS Blood and Transplant
North Bristol Park, Filton
Bristol
BS34 7QH
United Kingdom
Telephone: +44 1179217230
E-mail:
NUTS code: UK

Internet address(es):

Main address: www.nhsbt.nhs.uk

I.2)Joint procurement
I.3)Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at: www.bravosolutions.co.uk
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically via: www.bravosolutions.co.uk
Tenders or requests to participate must be submitted to the abovementioned address
I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Frozen, Non-UK Derived Pathogen Reduced Plasma.

II.1.2)Main CPV code
33141570
II.1.3)Type of contract
Supplies
II.1.4)Short description:

NHSBT requires pathogen reduced plasma which will then be subsequently manufactured into FFP, Single and pooled cryoprecipitate for paediatric and neonatal use, for recipients born on/after 1.1.1996. Those recipients are deemed not to have been exposed to the risk of vCJD in the UK food chain. Plasma must be sourced from a country outside the UK with vCJD prevalence >2.5 log lower than the UK. The TPSG approved the following countries for supply of plasma based on SaBTO 2013: Australia, Austria, Canada, Finland, New Zealand, Norway, Poland, Sweden and the US. For other transfusion transmitted infections the final component risk must be ‘no worse than current’ (detailed in the component specification).

The contract shall commence the date the contract is signed. The Term of the contract expires 2 years from the end of the Set Up Period. The Contract consists of a option to extend for 2 periods of 12 months. The Maximum Term of the Contract is 4 years from the end of the Set Up Period.

II.1.5)Estimated total value
II.1.6)Information about lots
This contract is divided into lots: no
II.2)Description
II.2.1)Title:
II.2.2)Additional CPV code(s)
33141510
II.2.3)Place of performance
NUTS code: UK
II.2.4)Description of the procurement:

NHS Blood and Transplant has a requirement to procure pathogen reduced plasma to be subsequently manufactured into components (fresh frozen plasma for paediatric and neonatal use, single and pooled cryoprecipitate for neonatal and paediatric use) for recipients born on or after 1.1.1996. Those recipients are deemed not to have been exposed to the risk of vCJD in the UK food chain and therefore plasma will be sourced from a country outside the UK with a vCJD prevalence > 2.5 log lower than the UK. The countries that are approved for the supply of plasma are Australia, Austria, Canada, Finland, New Zealand, Norway, Poland, Sweden and the United States (list approved by TPSG based on SaBTO report April 2013). Regarding other transfusion transmitted infections, the final component risk must be ‘no worse than current’ and is detailed within the component specification.

II.2.5)Award criteria
Criteria below
Price
II.2.6)Estimated value
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 48
This contract is subject to renewal: yes
Description of renewals:

NHSBT will look to tender for plasma via a competitive process at the end of the contract period.

II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: no
II.2.12)Information about electronic catalogues
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: no
II.2.14)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation
III.1.1)Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers
III.1.2)Economic and financial standing
III.1.3)Technical and professional ability
III.1.5)Information about reserved contracts
III.2)Conditions related to the contract
III.2.2)Contract performance conditions:
III.2.3)Information about staff responsible for the performance of the contract

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Open procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
IV.1.4)Information about reduction of the number of solutions or tenders during negotiation or dialogue
IV.1.6)Information about electronic auction
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: yes
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure
IV.2.2)Time limit for receipt of tenders or requests to participate
Date: 20/09/2017
Local time: 17:00
IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates
IV.2.4)Languages in which tenders or requests to participate may be submitted:
English
IV.2.6)Minimum time frame during which the tenderer must maintain the tender
Tender must be valid until: 18/04/2018
IV.2.7)Conditions for opening of tenders
Date: 20/09/2017
Local time: 17:00

Section VI: Complementary information

VI.1)Information about recurrence
This is a recurrent procurement: yes
VI.2)Information about electronic workflows
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
NHS Blood and Transplant
Bristol
United Kingdom
VI.4.2)Body responsible for mediation procedures
VI.4.3)Review procedure
VI.4.4)Service from which information about the review procedure may be obtained
VI.5)Date of dispatch of this notice:
18/08/2017